Last reviewed · How we verify
NCT05295901
The Effect of Mobile Health Applications on Symptom Control, Self-efficacy and Chronic Disease Management in COPD
NA trial testing mKOAH application in Pulmonary Disease, Chronic Obstructive in 80 participants. Status unknown.
30 August 2022
Quick facts
| Lead sponsor | Muş Alparslan University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 80 |
| Start date | 31 March 2022 |
| Primary completion | 30 August 2022 |
| Estimated completion | 15 February 2023 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- mKOAH application
Conditions studied
- Pulmonary Disease, Chronic Obstructive — all drugs for Pulmonary Disease, Chronic Obstructive →
Sponsor
Muş Alparslan University
Who can join
Eligibility, any sex, with Pulmonary Disease, Chronic Obstructive. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Name:The effect of the mobile application developed to provide symptom control in chronic obstructive pulmonary patients on self-efficacy and chronic disease management Aim:Considering the covid-19 pandemic seen all over the world, it is aimed to develop a mobile application with an integrated care model that allows individuals with chronic obstructive pulmonary disease to control their symptoms that seriously affect their quality of life.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05295901
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pulmonary Disease, Chronic Obstructive
Currently open trials in the same condition.
- NCT07177339 — eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (CO · Phase 3 · recruiting
- NCT06961214 — Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and T · Phase 3 · recruiting
- NCT06959095 — Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and T · Phase 3 · recruiting
- NCT06890208 — Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave · recruiting
- NCT06712563 — Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting · recruiting
Other Muş Alparslan University trials
Trials by the same sponsor.
- NCT07507695 — Acute Effects of Patellar Tendon Ultrasound on Countermovement Jump Performance · NA · not yet recruiting
- NCT07297628 — Teaching Caring Through '1 Concept-1 Minute · NA · not yet recruiting
- NCT07397221 — Oropharyngeal Humidification After Extubation on Thirst · NA · not yet recruiting
- NCT07355244 — Self-Affirmation Intervention After Mastectomy · NA · not yet recruiting
- NCT07274553 — Mindfulness-Based Stress Reduction for Adolescents: Effects on Game Addiction, Stress, and Sleep · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05295901 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Muş Alparslan University
- Last refreshed: 9 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05295901.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing